ArticlePLOS global public health2026
The Health of Nations Fund: Financing global drug development.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We explore the design and performance of a "Health of Nations Fund," a proposed securitization of a biomedical "megafund" that pools capital to invest in a diversified set of global drug development projects. Incorporating assets from four stages of the drug development process as well as royalties from approved therapeutics across eight therapeutic areas, our Monte Carlo simulations show that such a megafund can deliver an annual expected return of 12.0% with a Sharpe ratio of 1.37, indicating a favorable balance between risk and return. At the same time, it finances an average of 25 approved drugs that potentially benefit approximately 44 million patients worldwide over a 14.5-year horizon. To enhance the fund's financial and therapeutic value, we integrate an optimization framework into our design that accounts for global disease prevalence and severity, allowing investors to adjust the allocation of capital according to their preferences for financial performance and healthcare impact. Sensitivity analyses indicate that this megafund typically generates double-digit annual returns across most scenarios.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.